Subscribe To
CLBS / Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics
Content Topics
Caladrius
Biosciences
Merge
With
Privately
Held
Cend
Privately held
Therapeutics
Stock
CLBS
CLBS News
By Seeking Alpha
August 4, 2022
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q2 2022 Results - Earnings Call Transcript
Caladrius Biosciences, Inc. (NASDAQ:CLBS ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants John Menditto - VP, IR & Cor more_horizontal
By Seeking Alpha
May 5, 2022
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2022 Results - Earnings Call Transcript
Caladrius Biosciences, Inc. (NASDAQ:CLBS ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants John Menditto - VP, Investor R more_horizontal
By Benzinga
April 27, 2022
Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics
Caladrius Biosciences Inc (NASDAQ: CLBS) and privately-held Cend Therapeutics Inc have agreed to merge in an all-stock approximate "merger of equa more_horizontal
By Seeking Alpha
March 22, 2022
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2021 Results - Earnings Call Transcript
Caladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2021 Results - Earnings Call Transcript more_horizontal